Nivolumab: tested on its own
215 studies: no other medicine in its arm. Page 2 of 3. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.
- Phase I Biomarker Study (BMS-936558)CompletedNCT01358721Phase 1Results postedReport a problem
- BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)CompletedNCT01354431Phase 2Results postedReport a problem
- ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in JapanCompletedNCT00836888Phase 1Results postedReport a problem
- A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent MalignanciesCompletedNCT00730639Phase 1Results postedReport a problem
- A Study of MDX-1106 in Patients With Selected Refractory or Relapsed MalignanciesCompletedNCT00441337Phase 1Results postedReport a problem
- TACE With Immune Agents for Angiogenesis in Hepatocellular CarcinomaCompletedNCT07053202Not applicableReport a problem
- Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinActive, not recruitingNCT06640530Phase 3Report a problem
- Agnostic Therapy in Rare Solid TumorsActive, not recruitingNCT06638931Phase 2Report a problem
- Nivolumab in Multiple Myeloma Patients After Idecabtagene VicleucelActive, not recruitingNCT06523621Phase 2Report a problem
- A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinActive, not recruitingNCT06112808Phase 1Report a problem
- A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic MelanomaActive, not recruitingNCT06054555Phase 3Report a problem
- A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected MelanomaCompletedNCT05907122Phase 3Report a problem
- NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHNCompletedNCT05802290Phase 3Report a problem
- Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin LymphomaStatus unknownNCT05660993Phase 2Report a problem
- Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 StudyActive, not recruitingNCT05491616Phase 2Report a problem
- Neoadjuvant Anti-PD1 in HCCCompletedNCT05471674Phase 2Report a problem
- Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic CancerTerminatedNCT05435053Phase 2Report a problem
- Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at LymphodepletionStatus unknownNCT05385263Phase 2Report a problem
- Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant LesionsActive, not recruitingNCT05327270Phase 1Report a problem
- Nivolumab for Recurrent/Metastatic CarcinosarcomaStatus unknownNCT05224999Phase 2Report a problem
- Neoadjuvant Nivolumab for Upper Tract Urothelial CarcinomaStatus unknownNCT05160285Phase 2Report a problem
- Neo-NTP-CRT for Locally Advanced ESCCStatus unknownNCT05130684Phase 2Report a problem
- Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 ExpressionActive, not recruitingNCT04957615Phase 2Report a problem
- Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT04910347Phase 2Report a problem
- Pre-operative Immunotherapy in Stage II-III Urothelial CancerCompletedNCT04871594Phase 1Report a problem
- A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System LymphomaStatus unknownNCT04845139Not applicableReport a problem
- A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid CancersStatus unknownNCT04761744Phase 2Report a problem
- Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.CompletedNCT04749602Phase 2Report a problem
- Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCCTerminatedNCT04659369Phase 1Report a problem
- A Study of BMS-936558 With SBRT After Induction Chemotherapy in CholangiocarcinomaTerminatedNCT04648319Phase 2Report a problem
- Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCCCompletedNCT04611165Phase 2Report a problem
- A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT04603248Not applicableReport a problem
- Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) InfectionStatus unknownNCT04413838Phase 2Report a problem
- Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line ChemotherapyCompletedNCT04401774Phase 2Report a problem
- Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant CyclophosphamideWithdrawnNCT04361058Phase 1Report a problem
- COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1Status unknownNCT04356508Phase 2Report a problem
- Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.Status unknownNCT04343144Phase 2Report a problem
- Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young AdultsActive, not recruitingNCT04323046Phase 1Report a problem
- Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk MelanomaActive, not recruitingNCT04309409Phase 3Report a problem
- Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung CancerCompletedNCT04271384Phase 2Report a problem
- Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.TerminatedNCT04212026Phase 2Report a problem
- Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity StudyCompletedNCT04123925Phase 2Report a problem
- STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic AdenocarcinomaCompletedNCT04098432Phase 1/2Report a problem
- Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)CompletedNCT04091490Phase 2Report a problem
- Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation TherapyActive, not recruitingNCT04085250Phase 2Report a problem
- Nivolumab and Eribulin in HER2 Negative Metastatic Breast CancerStatus unknownNCT04061863Phase 1/2Report a problem
- A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLCStatus unknownNCT04023617Phase 2Report a problem
- Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS LymphomaCompletedNCT04022980Phase 1Report a problem
- Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With MelanomaStatus unknownNCT04021420Phase 1/2Report a problem
- Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing CystectomyStatus unknownNCT03993249Phase 2Report a problem
- Neoadjuvant Nivolumab for Operable Esophageal CarcinomaStatus unknownNCT03987815Phase 2Report a problem
- A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete ResectionCompletedNCT03980314Phase 1Report a problem
- Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade GliomasCompletedNCT03925246Phase 2Report a problem
- Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response PredictionStatus unknownNCT03843515Phase 1Report a problem
- Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx CancerCompletedNCT03838263Phase 2Report a problem
- Nivolumab in Patients With Advanced Cutaneous Squamous Cell CarcinomaStatus unknownNCT03834233Phase 2Report a problem
- Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical ResectionTerminatedNCT03812562Early Phase 1Report a problem
- Nivolumab Based Immunotherapy for Treatment of High Grade Cervical DysplasiaWithdrawnNCT03808168Phase 2Report a problem
- Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain MetastasesCompletedNCT03807765Phase 1Report a problem
- Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.WithdrawnNCT03758729Phase 2Report a problem
- Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell TumorsWithdrawnNCT03726281Phase 2Report a problem
- CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity CancerCompletedNCT03721757Phase 2Report a problem
- Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)Active, not recruitingNCT03703050Phase 2Report a problem
- Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune DiseaseTerminatedNCT03656627Phase 1Report a problem
- Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by ElectroporationTerminatedNCT03630640Phase 2Report a problem
- Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance TherapyStatus unknownNCT03569696Phase 2Report a problem
- Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the BladderStatus unknownNCT03529890Phase 2Report a problem
- Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 TherapyActive, not recruitingNCT03480334Phase 2Report a problem
- Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell CarcinomaCompletedNCT03469713Phase 2Report a problem
- Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous ChemotherapyWithdrawnNCT03390738Phase 2Report a problem
- A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationActive, not recruitingNCT03383458Phase 3Report a problem
- A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCCCompletedNCT03380130Phase 2Report a problem
- Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLCStatus unknownNCT03371992Early Phase 1Report a problem
- Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins LymphomaCompletedNCT03343665Phase 1/2Report a problem
- ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT03337919Phase 2Report a problem
- REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck TumorsCompletedNCT03317327Phase 1/2Report a problem
- Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi SarcomaCompletedNCT03316274Early Phase 1Report a problem
- Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1Status unknownNCT03313544Phase 4Report a problem
- Immunotherapy by Nivolumab for HIV+ PatientsCompletedNCT03304093Phase 2Report a problem
- Neoadjuvant Immunoradiotherapy in Head & Neck CancerActive, not recruitingNCT03247712Phase 1/2Report a problem
- Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3AActive, not recruitingNCT03245021Phase 1Report a problem
- Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal CancerActive, not recruitingNCT03233711Phase 3Report a problem
- Nivolumab in Recurrent and/or Metastatic SCCHNCompletedNCT03226756Phase 2Report a problem
- Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder CancerActive, not recruitingNCT03171025Phase 2Report a problem
- Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell TransplantationStatus unknownNCT03146468Phase 2Report a problem
- Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)Active, not recruitingNCT03134118Phase 2Report a problem
- Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and NeckCompletedNCT03132038Phase 2Report a problem
- Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung CancerWithdrawnNCT03121417Phase 2Report a problem
- Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung CancerActive, not recruitingNCT03110978Phase 2Report a problem
- Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG ImmunotherapyTerminatedNCT03106610Phase 1Report a problem
- CheckpOiNt Blockade For Inhibition of Relapsed MesotheliomaCompletedNCT03063450Phase 3Report a problem
- Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)Status unknownNCT03040791Phase 2Report a problem
- Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular CarcinomaCompletedNCT03033446Phase 2Report a problem
- Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal DiseaseActive, not recruitingNCT03025256Phase 1Report a problem
- Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation LoadsWithdrawnNCT03023904Phase 2Report a problem
- Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic RegimenCompletedNCT03013335Phase 2Report a problem
- Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer TypesCompletedNCT03012581Phase 2Report a problem
- Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic ChordomaCompletedNCT02989636Phase 1Report a problem
- Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic MalignanciesTerminatedNCT02985554Phase 1Report a problem
- Combining Radiosurgery and Nivolumab in the Treatment of Brain MetastasesCompletedNCT02978404Phase 2Report a problem